Vijendar Dwarakanath Portfolio
Invests via Napean Trading & Investment Co (Singapore) PTE Ltd | Managed by Vijendar Dwarakanath
Invests via Napean Trading & Investment Co (Singapore) PTE Ltd
Managed by Vijendar Dwarakanath
Automatically Tracked
Vijendar Dwarakanath Profile
Veteran life-sciences investor and entrepreneur focused on early-stage biotechnology and oncology therapeutics. Vijendar Dwarakanath combines operating R&D experience with venture investing, serving on corporate boards and advising clinical-stage companies. Known for sourcing translational assets, structuring financing rounds, and navigating regulatory and partnering pathways.
Veteran life-sciences investor and entrepreneur focused on early-stage biotechnology and oncology therapeutics. Vijendar Dwarakanath combines operating R&D experience with venture investing, serving on corporate boards and advising clinical-stage companies. Known for sourcing translational assets, structuring financing rounds, and navigating regulatory and partnering pathways.
Investment Philosophy & Strategy
Combines operational R&D experience with venture-style, early-stage biotech investing, prioritizing translational oncology assets with clear clinical paths and partnerable mechanisms. Uses deep scientific due diligence and milestone-driven, staged capital to de-risk programs, preferring syndication with strategic pharma and experienced co-investors. Active governance and hands-on portfolio support accelerate development, regulatory strategy, and partnering readiness. Time horizon is long, patient capital calibrated to clinical inflection points; risk discipline centers on robust preclinical-to-clinic evidence, clear go/no-go criteria, and exit through strategic partnerships or clinical value creation.
Combines operational R&D experience with venture-style, early-stage biotech investing, prioritizing translational oncology assets with clear clinical paths and partnerable mechanisms. Uses deep scientific due diligence and milestone-driven, staged capital to de-risk programs, preferring syndication with strategic pharma and experienced co-investors. Active governance and hands-on portfolio support accelerate development, regulatory strategy, and partnering readiness. Time horizon is long, patient capital calibrated to clinical inflection points; risk discipline centers on robust preclinical-to-clinic evidence, clear go/no-go criteria, and exit through strategic partnerships or clinical value creation.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
24.44%
Gain -2.87%
Monthly
1.47%
Yearly
19.32%
Drawdown
19.07%
$0
Equity
Holdings
$0
Investment
$0
$90.92M
Profit -$12.86M
Realized
$90.92M
Unrealized
$0
Dividends
$2.16M
Goals
Avg. 41% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-2.87%
Profit
-$12.86M
Win %
55%
This Week
Compared To Last Week
Gain
-3.59%
Profit
-$14.5M
Win %
55%
This Month
Compared to last month
Gain
-8.62%
Profit
-$36.72M
Win %
55%
This Year
Compared to last year
Gain
-3.69%
Profit
-$14.92M
Win %
54%
HOOD Robinhood Markets, Inc.
+$44.42M
NFLX Netflix, Inc.
+$8.35M
AMZN Amazon.com Inc
+$7.68M
META Meta Platforms Inc Class A
+$7.61M
AVGO Broadcom Inc.
+$7.55M
GOOGL Alphabet Inc
+$6.06M
SHOP Shopify Inc.
+$4.4M
NVDA NVIDIA Corporation
+$4.2M
BE Bloom Energy Corporation
+$3.88M
AAPL Apple Inc.
+$3.65M
CRWD CrowdStrike Holdings, Inc.
+$3.61M
RSP Invesco S&P 500 Equal Weight ETF
+$2.57M
TJX The TJX Companies, Inc.
+$2.37M
MSFT Microsoft Corp.
+$2.31M
MA Mastercard Incorporated
+$1.43M
OLED Universal Display Corporation
+$1.35M
BKNG Booking Holdings Inc.
+$1.33M
MRVL Marvell Technology, Inc.
+$1.21M
NOW ServiceNow, Inc.
+$1.18M
OKTA Okta Inc.
+$887,007.86
PINS Pinterest, Inc. Class A
+$849,137.95
XLV Health Care Select Sector SPDR Fund
+$811,115.95
IOT Samsara Inc. Class A Common Stock
+$772,613.6
LRCX Lam Research Corporation
+$681,314.92
SNOW Snowflake Inc.
+$678,563.96
P Everpure Inc.
+$609,921.76
MCK McKesson Corporation
+$603,160.05
PYPL PayPal Holdings Inc
+$568,629.8
INTU Intuit Inc.
+$541,380.08
ABNB Airbnb, Inc.
+$517,505.3
HD The Home Depot, Inc.
+$499,542.89
AZO AutoZone Inc.
+$390,945.55
ANET
ANET
+$338,667.68
SQ Block, Inc.
+$285,454.56
ICE Intercontinental Exchange, Inc.
+$170,834.4
LSCC Lattice Semiconductor Corporation
+$164,017.66
NTNX Nutanix, Inc.
+$77,383.28
ICLR ICON plc
-$3.87M
TEAM Atlassian Corporation Class A
-$2.28M
MDB MongoDB Inc.
-$2.27M
ANET Arista Networks, Inc.
-$1.38M
ADBE Adobe Inc.
-$1.16M
SNPS Synopsys, Inc.
-$1.08M
RBLX Roblox Corporation
-$947,589
APTV Aptiv PLC
-$852,285.15
ELV Elevance Health, Inc.
-$782,426.24
CRL Charles River Laboratories International, Inc.
-$760,144.27
FIVN Five9 Inc.
-$502,622
AMD Advanced Micro Devices, Inc.
-$406,336.84
TGT Target Corporation
-$387,907.47
MNST Monster Beverage Corporation
-$376,829.45
ADSK Autodesk, Inc.
-$370,322.2
DHR Danaher Corporation
-$163,055.57
STZ Constellation Brands, Inc.
-$134,723.47
ANSS Ansys, Inc.
-$117,813
WDAY Workday Inc.
-$107,925
YI 111, Inc. ADR
-$60,939.64
Z Zillow Group Inc.
-$59,750
KVYO Klaviyo Inc.
-$57,500
UNH UnitedHealth Group Incorporated
-$44,644.32
U Unity Software Inc.
-$24,340.63
UBER Uber Technologies, Inc.
-$18,952
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 163 | Longs Won 93/163 57% | Profit Factor 5.73 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $3.28M |
| Average Win $1.36M | Best Trade (Mar 30) $38.65M | Sharpe Ratio -11.76 |
| Average Loss -$314,487.51 | Worst Trade (Mar 30) -$1.88M | Z-Score -3.59 (100%) |
| Commissions $0 | Avg. Trade Length 7m 2w 5d | Expectancy $557,815.93 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Vijendar Dwarakanath?
The largest contributions to the portfolio's profits come from the following stocks: Robinhood Markets, Inc - $44.42M, Netflix, Inc - $8.35M, Amazon.com Inc - $7.68M, Meta Platforms Inc Class A - $7.61M, and Broadcom Inc - $7.55M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: ICON plc - $3.87M, Atlassian Corporation Class A - $2.28M, MongoDB Inc - $2.27M, Arista Networks, Inc - $1.38M, and Adobe Inc - $1.16M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Vijendar Dwarakanath's portfolio generate?
The portfolio generates substantial dividend income, with a total of $2.16M earned over time. The largest contributors to dividend income include UnitedHealth Group Incorporated - $380,878.42, Invesco S&P 500 Equal Weight ETF - $241,310.71, The TJX Companies, Inc - $184,045.07, Microsoft Corp - $164,370.54, and The Home Depot, Inc - $152,336.85. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Vijendar Dwarakanath's monthly returns?
Vijendar Dwarakanath's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Vijendar Dwarakanath's strategy be considered aggressive or moderate?
It is difficult to clearly classify Vijendar Dwarakanath's strategy as aggressive or moderate based on the available data. A more complete performance and portfolio structure history would be needed to assess the overall risk profile with confidence.
Should beginners follow Vijendar Dwarakanath's strategy?
It is difficult to determine whether Vijendar Dwarakanath's strategy is suitable for beginners based on the available data. A more complete view of performance, risk, and portfolio structure would be needed for a confident assessment.
